MEDP:NGS-Medpace Holdings Inc. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 312.36

Change

0.00 (0.00)%

Market Cap

USD 1.47B

Volume

0.34M

Analyst Target

USD 118.40
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Medpace Holdings Inc is a clinical contract research organisation. It is engaged in providing scientifically-driven clinical research-based drug and medical device development services to the biotechnology, pharmaceutical and medical device industries.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-30 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 33.82B
NTRA Natera Inc

N/A

USD 21.03B
ICLR ICON PLC

N/A

USD 14.94B
ILMN Illumina Inc

N/A

USD 14.06B
EXAS EXACT Sciences Corporation

N/A

USD 8.47B
GH Guardant Health Inc

N/A

USD 4.85B
RDNT RadNet Inc

N/A

USD 3.68B
SHC Sotera Health Co

N/A

USD 3.23B
WGS GeneDx Holdings Corp.

N/A

USD 2.75B
VCYT Veracyte Inc

N/A

USD 2.48B

ETFs Containing MEDP

AJEUAS:SW UBS (Irl) Fund Solutions .. 96.30 % 0.00 %

N/A

N/A
S6EW:SW Ossiam STOXX® Europe 600.. 4.65 % 0.00 %

N/A

USD 0.11B
AMID Argent Mid Cap ETF 3.71 % 0.00 %

N/A

N/A
ICLN iShares Global Clean Ener.. 3.63 % 0.46 %

N/A

USD 1.34B
INRG:SW iShares Global Clean Ener.. 3.62 % 0.00 %

N/A

USD 1.93B
EUDV:SW SPDR® S&P Euro Dividend .. 3.48 % 0.00 %

N/A

N/A
XCLN:CA iShares Global Clean Ener.. 3.46 % 0.00 %

N/A

CAD 9.01M
INRE:PA iShares Global Clean Ener.. 3.45 % 0.00 %

N/A

N/A
FNRG:LSE 2.84 % 0.00 %

N/A

N/A
STUX:SW SPDR® MSCI Europe Utilit.. 2.32 % 0.00 %

N/A

USD 0.16B
NRJL:LSE Lyxor MSCI New Energy ESG.. 2.08 % 0.00 %

N/A

USD 0.58B
QSML:AU VanEck MSCI International.. 1.45 % 0.00 %

N/A

N/A
RFG Invesco S&P MidCap 400® .. 0.00 % 0.35 %

N/A

N/A
JSMD Janus Henderson Small/Mid.. 0.00 % 0.50 %

N/A

USD 0.43B
SMLF iShares MSCI USA Small-Ca.. 0.00 % 0.30 %

N/A

N/A
INRG:LSE iShares Global Clean Ener.. 0.00 % 0.00 %

N/A

N/A
L6EW:LSE Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

N/A

USD 0.11B
LCPE:LSE Ossiam Shiller Barclays C.. 0.00 % 0.00 %

N/A

USD 0.13B
S6EW:LSE Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

N/A

N/A
JELS:LSE 0.00 % 0.00 %

N/A

N/A
UTIL:LSE SPDR® MSCI Europe Utilit.. 0.00 % 0.00 %

N/A

USD 0.17B
XS6R:LSE Xtrackers MSCI Europe Uti.. 0.00 % 0.00 %

N/A

USD 0.03B
S6EW:PA Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

N/A

USD 0.11B
STU:PA SPDR® MSCI Europe Utilit.. 0.00 % 0.00 %

N/A

USD 0.17B
IQQH:F iShares Global Clean Ener.. 0.00 % 0.00 %

N/A

N/A
OSX6:F Ossiam Lux - Ossiam Stoxx.. 0.00 % 0.00 %

N/A

N/A
SPYU:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

N/A
SPYW:F SPDR S&P Euro Dividend Ar.. 0.00 % 0.00 %

N/A

N/A
DXSH:XETRA Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

N/A

USD 0.03B
IQQH:XETRA iShares Global Clean Ener.. 0.00 % 0.00 %

N/A

N/A
OSX6:XETRA Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

N/A

N/A
SPYU:XETRA SPDR® MSCI Europe Utilit.. 0.00 % 0.00 %

N/A

N/A
ZCLN:CA BMO Clean Energy Index ET.. 0.00 % 0.00 %

N/A

CAD 0.05B
IBBJ 0.00 % 0.00 %

N/A

N/A
VCLN Virtus Duff & Phelps Clea.. 0.00 % 0.00 %

N/A

USD 5.42M

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.98% 73% C 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.98% 73% C 51% F
Trailing 12 Months  
Capital Gain -22.71% 55% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.71% 55% F 37% F
Trailing 5 Years  
Capital Gain 325.67% 93% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 325.67% 93% A 92% A
Average Annual (5 Year Horizon)  
Capital Gain 38.23% 79% B- 85% B
Dividend Return 38.23% 79% B- 85% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 39.61% 77% C+ 47% F
Risk Adjusted Return 96.53% 100% F 95% A
Market Capitalization 1.47B 90% A- 93% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 128.40 48% 36%
Price/Book Ratio 12.09 10% 10%
Price / Cash Flow Ratio 16.38 24% 19%
Price/Free Cash Flow Ratio 19.82 20% 18%
Management Effectiveness  
Return on Equity 58.42% 100% 98%
Return on Invested Capital 54.22% 100% 94%
Return on Assets 14.86% 98% 98%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.